Literature DB >> 22071591

Progress toward poliomyelitis eradication--Afghanistan and Pakistan, January 2010-September 2011.

.   

Abstract

Indigenous transmission of wild poliovirus (WPV) has never been interrupted in Afghanistan, Pakistan, India, and Nigeria. Among those countries, Afghanistan and Pakistan represent a common epidemiologic reservoir. This report updates previous reports (1,4) and describes polio eradication activities and progress in Afghanistan and Pakistan during January 2010--September 2011, as of October 31, 2011, and planned activities during 2011--2012 to address challenges to polio eradication. In Afghanistan, WPV transmission during 2010--2011 predominantly occurred in the conflict-affected South Region and the adjacent Farah Province of the West Region. During 2010, 25 WPV cases were confirmed in Afghanistan, compared with 38 in 2009; 42 WPV cases were confirmed during January--September 2011, compared with 19 for the same period in 2010. In Pakistan, WPV transmission during 2010--2011occurred both in conflict-affected, inaccessible areas along the common border with Afghanistan and in accessible areas; 144 WPV cases were confirmed in 2010, compared with 89 in 2009, and 120 WPV cases were confirmed during January--September 2011, compared with 93 during the same period in 2010. In Pakistan, the president launched a National Emergency Action Plan for polio eradication in January 2011, emphasizing the key role and responsibility of political and health-care leaders at the district and subdistrict (union council) levels. Enhanced commitment, management, and oversight by provincial and district authorities will be needed to achieve further progress toward interruption of WPV transmission in Pakistan. Continued efforts also will be needed to enhance the safety of vaccination teams within insecure areas of both countries.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22071591

Source DB:  PubMed          Journal:  MMWR Morb Mortal Wkly Rep        ISSN: 0149-2195            Impact factor:   17.586


  7 in total

1.  Progress and peril: poliomyelitis eradication efforts in Pakistan, 1994-2013.

Authors:  James P Alexander; Mufti Zubair; Muzaffar Khan; Nima Abid; Elias Durry
Journal:  J Infect Dis       Date:  2014-11-01       Impact factor: 5.226

2.  Progress toward poliomyelitis eradication - Afghanistan, January 2012-September 2013.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2013-11-22       Impact factor: 17.586

3.  Progress toward poliomyelitis eradication - Pakistan, January 2012-September 2013.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2013-11-22       Impact factor: 17.586

4.  The role of supplementary environmental surveillance to complement acute flaccid paralysis surveillance for wild poliovirus in Pakistan - 2011-2013.

Authors:  Tori L Cowger; Cara C Burns; Salmaan Sharif; Howard E Gary; Jane Iber; Elizabeth Henderson; Farzana Malik; Syed Sohail Zahoor Zaidi; Shahzad Shaukat; Lubna Rehman; Mark A Pallansch; Walter A Orenstein
Journal:  PLoS One       Date:  2017-07-25       Impact factor: 3.240

5.  Routine immunization in Pakistan: comparison of multiple data sources and identification of factors associated with vaccination.

Authors:  Hafsa Imran; Dania Raja; Nicholas C Grassly; M Zubair Wadood; Rana M Safdar; Kathleen M O'Reilly
Journal:  Int Health       Date:  2018-03-01       Impact factor: 2.473

6.  Molecular characterization and phylogenetic relationship of wild type 1 poliovirus strains circulating across Pakistan and Afghanistan bordering areas during 2010-2012.

Authors:  Shahzad Shaukat; Mehar Angez; Muhammad Masroor Alam; Salmaan Sharif; Adnan Khurshid; Farzana Malik; Lubna Rehman; Syed Sohail Zahoor Zaidi
Journal:  PLoS One       Date:  2014-09-17       Impact factor: 3.240

7.  A New Method for Estimating the Coverage of Mass Vaccination Campaigns Against Poliomyelitis From Surveillance Data.

Authors:  K M O'Reilly; A Cori; E Durry; M Z Wadood; A Bosan; R B Aylward; N C Grassly
Journal:  Am J Epidemiol       Date:  2015-11-14       Impact factor: 4.897

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.